S. Hodi

发表

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2017, The New England journal of medicine.

Ipilimumaband Its Toxicities : AMultidisciplinaryApproach

Leslie, Å., F., 2013 .

7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response

S. O’Day, E. Hersh, W. Urba, 2007 .

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

D. Jackson, M. Delorenzi, Lin Zhang, 2019, Cancer cell.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Emily M. Thrash, A. Giobbie-Hurder, Helen X. Chen, 2021, Clinical Cancer Research.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies

G. Curigliano, A. Santoro, A. Naing, 2019, Clinical Trials.

Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy

G. Curigliano, A. Santoro, S. Gutzwiller, 2019, Annals of Oncology.

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

J. Desai, Robert W. Hsieh, K. Morrissey, 2020 .

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Axel Hoos, Jedd D. Wolchok, J. Wolchok, 2009, Clinical Cancer Research.

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

F. Hodi, H. Hatabu, M. Nishino, 2017, Nature Reviews Clinical Oncology.

Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

F. Hodi, S. Hodi, Daniel S. Chen, 2012, Clinical Cancer Research.

Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma

F. Hodi, J. Luke, S. Hodi, 2011, Clinical Cancer Research.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

M. Atkins, F. Hodi, H. Tawbi, 2018, The New England journal of medicine.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

A. Giobbie-Hurder, F. Hodi, M. Nishino, 2013, Clinical Cancer Research.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013

B. Schilling, F. Marincola, R. Sullivan, 2014, Journal of Translational Medicine.

PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

F. Hodi, H. Hatabu, P. Ott, 2016, Clinical Cancer Research.

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

F. Hodi, S. O’Day, T. Guthrie, 2016, Journal of Immunotherapy for Cancer.

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

F. Hodi, M. Nishino, N. Ramaiya, 2014, Journal of Immunotherapy for Cancer.

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

J. Machiels, K. Korski, G. Meneses‐Lorente, 2022, Journal for ImmunoTherapy of Cancer.

Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma

J. Luke, S. Hodi, Stephen F. Hodi, 2011, Clinical Cancer Research.

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

A. Giobbie-Hurder, M. Nishino, N. Ramaiya, 2013, Clinical Cancer Research.

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

A. Giobbie-Hurder, J. Wargo, F. Hodi, 2012, Clinical Cancer Research.

Cytotoxic T-Lymphocyte–Associated Antigen-4

F. Hodi, A. Salama, S. Hodi, 2007, Clinical Cancer Research.

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

A. Giobbie-Hurder, R. Sullivan, P. Ott, 2021, Journal for ImmunoTherapy of Cancer.

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

A. Giobbie-Hurder, F. Hodi, H. Maecker, 2018, Journal of Immunotherapy for Cancer.